NovaBridge Biosciences (NBP) Stock Research
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Latest price: 1.36 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Dennis Phillip Andrew | sell | 2026-09-18 | 5828.39 |
| Cao Sean Wuxiong | sell | 2026-09-09 | 79903.72 |
| Xu Cong Claire | sell | 2026-08-31 | 2592.78 |
| Xu Cong Claire | sell | 2026-07-06 | 3991.65 |
| Dennis Phillip Andrew | sell | 2026-06-18 | 5606.04 |
| Cao Sean Wuxiong | sell | 2026-05-14 | 42584.01 |
| Hagler Mark Arnold | buy | 2026-04-24 | 577300 |